Study of early breast cancer outcomes after surgery
Part of Cancer, Skin clinical trials.
This study looks at medical records of people with a common type of early breast cancer to understand how often the cancer comes back after surgery. It helps doctors learn more about which patients might have a higher or lower risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with early-stage breast cancer between January 2010 and December 2023.
- You were 18 or older when diagnosed.
- Your cancer was stage I, II, or III at diagnosis.
- Your cancer was hormone receptor-positive (HR+) and HER2-negative.
- You had surgery to remove the cancer, like a lumpectomy or mastectomy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with HER2-positive breast cancer who received chemotherapy and a targeted drug (trastuzumab) before surgery but did not have a complete response. Researchers want to understand which follow-up treatments work best to prevent cancer from coming back.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
This study follows people who have had breast cancer come back in the same area after surgery. It looks at how well re-treatment works and helps doctors understand how to manage this type of recurrence.
This study is looking at whether certain patient information can help predict if HR+/HER2- early breast cancer will come back. If you have had surgery and hormone therapy, your data might help improve future care.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This study collects health information about people who have had a breast cancer recurrence after breast-conserving (breast-saving) surgery. It helps researchers understand what happens after initial treatment and how local recurrences are managed.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.